Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
ConditionLung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Canadian College of Naturopathic Medicine
About this trial
This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
Eligibility criteria
Qualifiers
Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy
Disqualifiers
ECOG status greater than 2
Previously received IVC within 6 months prior to randomization
Biochemical deficiency in G6PD
Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min
Trial design
Treatments tested in this trial
- Ascorbic acid
- Normal Saline
Treatment groups
90 Participants
are divided into 2 treatment groupsSponsors and collaborators
The Canadian College of Naturopathic Medicine
Lead sponsor
Ottawa Hospital Research Institute
Collaborator
Source ClinicalTrials.gov